Allogene Therapeutics launches underwritten public offering, suspends ATM sales

Allogene Therapeutics, Inc.

Company announced proposed underwritten public offering of common stock on April 13, 2026.
Sales under existing ATM agreement with TD Securities are suspended pending new prospectus.
No offering size or pricing details disclosed in the 8-K; further supplement expected.
Proceeds intended for general corporate purposes; dilution to existing shareholders anticipated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.